Portfolio company
Ambagon Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops small-molecule stabilisers to modulate protein interactions for the treatment of cancer and other serious diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Amphista Therapeutics
This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
KyDo Therapeutics
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
Accent Therapeutics
This biopharmaceutical company develops small molecule precision therapies for patients with various types of cancer.
Frontier Medicines
This biopharmaceutical company develops small-molecule precision medicines targeting undruggable proteins for patients with cancer and immunological diseases.
Ligature Therapeutics
This biotech company develops protein degrader therapeutics using a fragment-based discovery platform to treat intractable diseases for patients with cancer.
Sibylla Biotech
This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.